Clinical significance of B7-H4 expression in matched non-small cell lung cancer brain metastases and primary tumors

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 869-875

  Li, Zhen Ye ^b   Zhang, Xiang Heng ^a   Chen, Yu ^a   Guo, Jian Gui ^a   Sai, Ke ^a   Yang, Qun Ying ^a   Chen, Zhong Ping ^a   Mou, Yong Gao ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

B7 H4; Brain metastases; Immunotherapy; Non small cell lung cancer

Indexed keywords

V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; OVERALL SURVIVAL; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SURVIVAL RATE; SURVIVAL TIME;

EID: 84880088599     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S48085     Document Type: Article

References (36)

1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893-1907.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
3. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin. 2011;61(2):91-112.
4. Mamon HJ, Yeap BY, Janne PA, etal. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol. 2005;23(7):1530-1537.
5. Wang SY, Ye X, Ou W, Lin YB, Zhang BB, Yang H. Risk of cerebral metastases for postoperative locally advanced non-small-cell lung cancer. Lung Cancer. 2009;64(2):238-243.
6. Hubbs JL, Boyd JA, Hollis D, Chino JP, Saynak M, Kelsey CR. Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer. 2010;116(21):5038-5046.
7. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999;43(4):795-803.
8. Patchell RA, Tibbs PA, Walsh JW, etal. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494-500.
9. Andrews DW, Scott CB, Sperduto PW, etal. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665-1672.
10. Hotta K, Kiura K, Ueoka H, etal. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer. 2004;46(2):255-261.
11. Lee DH, Han JY, Lee HG, etal. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res. 2005;11(8):3032-3037.
12. Arnold SM, Young AB, Munn RK, Patchell RA, Nanayakkara N, Markesbery WR. Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1in paired primary tumors and brain metastasis. Clin Cancer Res. 1999;5(12): 4028-4033.
13. Saad AG, Yeap BY, Thunnissen FB, etal. Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma. Cancer. 2008;113(8):2129-2138.
14. Sica GL, Choi IH, Zhu G, etal. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003;18(6):849-861.
15. Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A. 2003;100(18):10388-10392.
16. Prasad DV, Richards S, Mai XM, Dong C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity. 2003;18(6):863-873.
17. Quandt D, Fiedler E, Boettcher D, Marsch WC, Seliger B. B7-H4 Expression in Human Melanoma: Its Association with Patients' Survival and Antitumor Immune Response. Clin Cancer Res. 2011;17(10): 3100-3111.
18. Tringler B, Zhuo S, Pilkington G, etal. B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res. 2005;11(5):1842-1848.
19. Sun Y, Wang Y, Zhao J, etal. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer. 2006;53(2):143-151.
20. Tringler B, Liu W, Corral L, etal. B7-H4 overexpression in ovarian tumors. Gynecol Oncol. 2006;100(1):44-52.
21. Krambeck AE, Thompson RH, Dong H, etal. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A. 2006;103(27): 10391-10396.
22. Zang X, Thompson RH, Al-Ahmadie HA, etal. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A. 2007;104(49):19458-19463.
23. Chen LJ, Sun J, Wu HY, etal. B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother. 2011;60(7): 1047-1055.
24. Awadallah NS, Shroyer KR, Langer DA, etal. Detection of B7-H4 and p53in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas. 2008;36(2):200-206.
25. Jiang J, Zhu Y, Wu C, etal. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother. 2010;59(11):1707-1714.
26. Gaspar L, Scott C, Rotman M, etal. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745-751.
27. Salceda S, Tang T, Kmet M, etal. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res. 2005;306(1):128-141.
28. Kryczek I, Wei S, Zhu G, etal. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 2007;67(18):8900-8905.
29. Yao Y, Wang X, Jin K, etal. B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells. J Neurooncol. 2008;89(2):121-129.
30. Wang X, Hao J, Metzger DL, etal. B7-H4 Treatment of T Cells Inhibits ERK, JNK, p38, and AKT Activation. PLoS One. 2012;7(1):e28232.
31. Yi KH, Chen L. Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev. 2009;229(1):145-151.
32. Hodi FS, O'Day SJ, McDermott DF, etal. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
33. Topalian SL, Hodi FS, Brahmer JR, etal. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26): 2443-2454.
34. Brahmer JR, Tykodi SS, Chow LQ, etal. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
35. Chinnadurai R, Grakoui A. B7-H4mediates inhibition of T cell responses by activated murine hepatic stellate cells. Hepatology. 2010;52(6):2177-2185.
36. Thompson RH, Zang X, Lohse CM, etal. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res. 2008;68(15):6054-6058.